Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction

Clinical trial NCT03041259 · UNKNOWN

Trial details

NCT number: NCT03041259
Sponsor: Reven Pharmaceuticals, Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Critical Limb Ischemia Peripheral Arterial Disease

Start date: 2020-01-01
Primary completion: 2022-01-01
Enrollment: 320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.